MedTrace Logo

Benefits of Hemodialysis With Citrate (ABC-treat) Study

NCT03319680 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-10-24

No results posted yet for this study

Summary

Prospective randomized cross-over multicenter study to demonstrate the benefits of hemodialysis without acetate dialysate, with citrate.

32 weeks duration, in two phases. In the first, half of the patients started with citrate dialysate for 16 weeks and the other half with acetate dialysate, and then patients cross.

The primary objective is to analyze the effect of citrate dialysate on acid base balance decreasing chronic metabolic acidosis and avoiding / reducing post-dialytic alkalosis.

Conditions

  • Hemodialysis-Induced Symptom

Interventions

OTHER

Citrate dialysate

Compare the effect of citrate dialysate with acetate dialysate

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Fundación Senefro

    lead OTHER

Principal Investigators

  • Rafael Perez-Garcia, PhD · Nephrology department. Hospital universitario Infanta Leonor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-10-31
Completion
2017-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03319680 on ClinicalTrials.gov